Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates. “We have been honored to have Kevin serve as the Lead Independent Director on the Gilead Board since 2020, a.

Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders

Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.

Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be.

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment

Intellia Therapeutics

bluebird bio

CRISPR Therapeutics

Many gene-editing biotechs are developing cures. Curing patients is good.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor (CAR) T-cell therapy Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplanta.

Kite's Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 11:30 AM ET Company Participants Dan O'Day - Chairman, Chief Executive Officer Andy Dickinson - Chief Financial Officer Conference Call Participants Terrence Flynn - Morgan Stanley Terrence Flynn Great. Thanks so much for joining us, everybody.

Gilead Sciences, Inc. (GILD) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study

AbbVie

Amgen

Bristol-Myers

Cardinal Health

Medtronic

Pfizer

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The results are being presented today at the.

Gilead's Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable in recent quarters, unlike Pfizer, whose demand for COVID-19 products fell sharply in the first half of 2023. Comirnaty sales were $1,488 million in Q2 2023, down 51.4% from the previous quarter, due to declining public interest in vaccinations and a sharp drop in COVID-19 hospitalizations.

Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans

Investors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said Friday as he upgraded GILD stock.

The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month

BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.

Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

Illumina

IQVIA Hlds

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Merck

Navistar

Omega Healthcare Investors

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close Septe.

Gilead Prices $2 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal All right. Thank you very much for joining us today.

Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)

Applied Materials

Dollar General

Danaher

Dolby Laboratories

Equinix

Garmin

Martin Marietta Materials

Monolithic Power Systems

M&T Bank

Norfolk Southern

Old Dominion Freight Line

SAP SE

Sony

Constellation Brands

Toronto-Dominion Bank

Thermo Fisher Scientific

TC Energy

Verisk Analytics

This article presents the highest-quality Dividend Challengers, companies listed on U.S. exchanges with consistently higher annual dividend payouts for 5-9 years. The top 20 highest-quality Dividend Challengers are identified based on a quality scoring system, with Toronto-Dominion Bank, Dolby Laboratories, and Thermo Fisher Scientific making the top three. The article also highlights stocks trading at favorable valuations and offering compelling metrics for income-focused, growth-oriented, value-driven, and total-return investors.

The Highest Quality Dividend Challenger Summary

Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.

Nearing Retirement? These Stocks Will Pay You For Life

Gilead Sciences is still deeply undervalued, which should lead to higher stock prices in the coming quarters. But maybe a catalyst is necessary to driver the stock price higher. While quarterly results were not enough, the expanded label for Veklury is most likely also not the catalyst we are searching for.

Gilead Sciences: Searching For A Catalyst

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following U.S. Food and Drug Administration (FDA) approval for Gilead's supplemental new drug application (sNDA) for the company's Veklury Covid-19 treatment. That covers its use as a treatment for patients with Covid-19 who are suffering from “mild, moderate and severe hepatic impairment.

GILD Stock Alert: FDA Expands Indications for Gilead Sciences' Veklury Covid-19 Treatment

Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sNDA) for Veklury.

GILD Stock Alert: FDA Approves Gilead Sciences' Veklury Covid-19 Treatment

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral COVID-19 treatment that can be used across all stages of liver d.

FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment

Roche Holding AG

Cancer drug stocks were boosted on Wednesday after Roche accidentally published positive interim results from its lung cancer treatment study. The Swiss drugmaker said that it had been made aware of the inadvertent disclosure of the second interim analysis from its Phase 3 study evaluating its investigational anti-TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains) immunotherapy tiragolumab in combination with the established immune-oncology drug Tecentriq for people with lung cancer.

Cancer drug stocks soar after Roche accidentally releases positive interim lung cancer trial results

iTeos Therapeutics, Inc.

Arcus Biosciences

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%, got a boost premarket on Wednesday after Roche AG RHHBY, -1.10% said there had been an “inadvertent disclosure” of interim data from a study of its anti-TIGIT therapy tiragolumab in non-small cell lung cancer. The interim results showed positive data for overall survival with tiragolumab, but the results were “not mature” at the time of the analysis that was disclosed, Roche said in a release.

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

News for Gilead Sciences Stock (GILD)